|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||13.87 - 14.64|
|52 Week Range||7.81 - 16.91|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.40|
Subscribe to Yahoo Finance Plus to view Fair Value for FGEN
Every investor in FibroGen, Inc. ( NASDAQ:FGEN ) should be aware of the most powerful shareholder groups. Insiders...
FibroGen (FGEN) delivered earnings and revenue surprises of 17.02% and 18.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021Continued significant roxadustat volume growth in China SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the company’s recent developments. “We continue making excellent progress with pamrevlumab across al